Navigation Links
Boston Scientific Announces Results for Fourth Quarter and Year Ended December 31, 2007
Date:2/4/2008

NATICK, Mass., Feb. 4 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the fourth quarter and full year ended December 31, 2007, as well as guidance for net sales and earnings per share (EPS) for the first quarter of 2008.

Fourth quarter highlights:

-- Achieved adjusted EPS of $0.24 and record net sales of $2.152 billion,

both exceeding most recently issued guidance

-- Grew cardiac rhythm management (CRM) sales 11 percent

-- Achieved 10 percent overall sales growth in product lines excluding

drug-eluting stents (DES) and CRM

-- Maintained leading position in the worldwide DES market

-- Launched restructuring program to reduce expenses and head count

-- Received CE Mark approvals for the use of the TAXUS(R) Liberte(TM)

stent system in diabetic patients, the CONFIENT(TM) ICD and the

LIVIAN(TM) CRT-D

"The turn that began last quarter continued this quarter, with strong adjusted earnings and record sales," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "For the year, we made substantial progress toward our goals of increasing shareholder value, restoring profitable sales growth and strengthening Boston Scientific for the future. We implemented a series of initiatives designed to focus and simplify our business, including expense and head count reductions and the sale of non- strategic assets. We reported record sales, and we achieved the leadership position in the global stent market. Perhaps our most meaningful progress came in quality, where we revolutionized our approach and changed our culture. Many of the steps we took in 2007 will help position us for the challp>

Acquisition and divestiture-related charges:

Loss on assets held for sale $208

Purchased research and development 13 2

Integration costs (a) (5) $19

Business optimization charges (b) 19

Step-up value of inventory sold ( c ) (12)

Fair-value adjustment for the sharing

of proceeds feature of the Abbott

Laboratories stock purchase (d) (5)

216 23

Income tax benefit (f) (5) -

Acquisition and divestiture-related

charges, net of tax $211 $23

Restructuring charges:

Restructuring charges (e) $184

Income tax benefit (f) (53)

Restructuring charges, net of tax $131

Litigation-related charges:

Litigation-related charges $365

Income tax benefit (f) (71)

Litigation-related charges, net of tax $294

Amortization expense:

Amortization expense $174 $174

Income tax expense (benefit) (f) 3 (32)

Amortization expense, net of tax $177 $142

(a) Recorded credits of $4 million in 2007 to selling, general and

administrative expenses and $1 million to research and development

expenses; recorded expenses of $2 million in 2006 to cost of

products sold, $7 million to selling, general and administrative

expenses and $10 million to research and development expenses.

(b) Recorded to selling, general and administrative expenses.

( c ) Recorded to cost of products sold.

(d) Recorded to other, net.

(e) Recorded $176 million to restructuring charges in 2007, $4 million

to selling, general and administrative expenses, $2 million to cost

of products sold, and $2 million to research and development

expenses.

(f) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item

in accordance with FASB Interpretation No. 18, "Accounting for

Income Taxes in Interim Periods.

BOSTON SCIENTIFIC CORPORATION

CONDENSED GAAP RESULTS OF OPERATIONS

(Unaudited)

Year Ended

December 31,

In millions, except per share data 2007 2006

Net sales $8,357 $7,821

Cost of products sold 2,342 2,207

Gross profit 6,015 5,614

Operating expenses

Selling, general and administrative expenses 2,909 2,675

Research and development expenses 1,091 1,008

Royalty expense 202 231

Amortization expense 641 530

Purchased research and development 85 4,119

Restructuring charges 176

Litigation-related charges 365

Loss on assets held for sale 560

6,029 8,563

Operating loss (14) (2,949)

Other income (expense):

Interest expense (570) (435)

Other, net 15 (151)

Loss before income taxes (569) (3,535)

Income tax (benefit) expense (74) 42

Net loss $(495) $(3,577)

Net loss per common share - assuming dilution $(0.33) $(2.81)

Weighted average shares outstanding -

assuming dilution 1,486.9 1,273.7

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET (LOSS) INCOME AND NET (LOSS) INCOME PER COMMON SHARE

RECONCILIATIONS

(Unaudited)

An explanation of the ways in which Boston Scientific management uses

these non-GAAP measures to evaluate its business, the substance behind

Boston Scientific management's decision to use these non-GAAP measures,

the material limitations associated with the use of these non-GAAP

measures, the manner in which Boston Scientific management compensates for

those limitations, and the substantive reasons why Boston Scientific

management believes that these non-GAAP measures provide useful

information to investors is included in the exhibit labeled "Use of Non-

GAAP Financial Measures.

Year Ended Year Ended

December 31, 2007 December 31, 2006

Impact per Impact per

In millions, except per Net income diluted Net income diluted

share data (loss) share (loss) share

GAAP results $(495) $(0.33) $(3,577) $(2.81)

Non-GAAP adjustments:

Acquisition and

divestiture-related

charges 667 0.44 4,566 3.58

Restructuring charges 131 0.09

Litigation-related charges 294 0.20

Amortization expense 560 0.37 421 0.32

Adjusted results $1,157 $0.77 (1) $1,410 $1.09 (2)

(1) Calculated by assuming stock-based dilution of 13.1 million shares

(2) Calculated by assuming stock-based dilution of 15.6 million shares

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET (LOSS) INCOME AND NET (LOSS) INCOME PER SHARE

RECONCILIATIONS (CONT.)

(Unaudited)

Year Ended

December 31,

2007 2006

Acquisition and divestiture-related charges:

Loss on assets held for sale $560

Purchased research and development 85 $4,186

Integration costs (a) 29 61

Fair-value adjustment for the sharing

of proceeds feature of the Abbott

Laboratories stock purchase (b) 8 95

Step-up value of inventory sold (c) 267

CRM technology offering charge (c) 31

Charitable donation (b) 5

Business optimization charges (d) 19

AAA program cancellation net credit (e) (36)

682 4,628

Income tax benefit (g) (15) (62)

Acquisition and divestiture-related

charges, net of tax $667 $4,566

Restructuring charges:

Restructuring charges (f) $184

Income tax benefit (g) (53)

Restructuring charges, net of tax $131

Litigation-related charges:

Litigation-related charges $365

Income tax benefit (g) (71)

Litigation-related charges, net of tax $294

Amortization expense:

Amortization expense $641 $530

Income tax benefit (g) (81) (109)

Amortization expense, net of tax $560 $421

(a) Recorded $6 million in 2007 to cost of products sold, $20 million to

selling, general and administrative expenses and $3 million to

research and development expenses; recorded $2 million in 2006 to

cost of products sold, $46 million to selling, general and

administrative expenses, and $13 million to research and development

expenses.

(b) Recorded to other, net.

( c ) Recorded to cost of products sold.

(d) Recorded in 2006 to selling, general and administrative expenses.

(e) Recorded a credit of $67 million to purchased research and

development and a charge of $31 million to research and development

expenses.

(f) Recorded $176 million to restructuring charges in 2007, $4 million

to selling, general and administrative expenses, $2 million to cost

of products sold, and $2 million to research and development

expenses.

(g) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item

in accordance with FASB Interpretation No. 18, "Accounting for

Income Taxes in Interim Periods.

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31,

In millions 2007 2006

Assets

Current assets:

Cash and cash equivalents $1,452 $1,668

Trade accounts receivable, net 1,502 1,388

Inventories 725 684

Deferred income taxes 963 583

Assets held for sale 1,099 1,447

Other current assets 464 474

Total current assets 6,205 6,244

Property, plant and equipment, net 1,735 1,644

Investments 317 596

Other assets 157 234

Intangible assets, net 23,067 22,378

$31,481 $31,096

Liabilities and Stockholders' Equity

Current liabilities:

Borrowings due within one year $256 $7

Accounts payable and accrued expenses 2,680 2,020

Liabilities associated with assets

held for sale 71 93

Other current liabilities 275 552

Total current liabilities 3,282 2,672

Long-term debt 7,933 8,895

Deferred income taxes 2,536 2,743

Other long-term liabilities 2,633 1,488

Stockholders' equity 15,097 15,298

$31,481 $31,096

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Three Months Ended

December 31, Change

As Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

DOMESTIC $1,226 $1,261 (3%) (3%)

Europe 479 426 13% 1%

Asia Pacific 326 262 24% 18%

Inter-Continental 121 116 4% (6%)

INTERNATIONAL 926 804 15% 6%

WORLDWIDE $2,152 $2,065 4% 1%

Three Months Ended

December 31, Change

As Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

Interventional Cardiology $785 $831 (6%) (9%)

Peripheral Interventions/

Vascular Surgery 158 160 (1%) (5%)

Electrophysiology 38 35 11% 8%

Neurovascular 92 83 10% 5%

Cardiac Surgery 50 49 3% 3%

Cardiac Rhythm Management 544 489 11% 7%

CARDIOVASCULAR 1,667 1,647 1% (2%)

Oncology 60 55 8% 4%

Endoscopy 223 198 13% 8%

Urology 108 98 10% 8%

ENDOSURGERY 391 351 11% 7%

NEUROMODULATION 94 67 40% 38%

WORLDWIDE $2,152 $2,065 4% 1%

Growth rates are based on actual, non-rounded amounts

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Year Ended

December 31, Change

As Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

DOMESTIC $4,923 $4,840 2% 2%

Europe 1,807 1,576 15% 5%

Asia Pacific 1,176 948 24% 23%

Inter-Continental 451 457 (1%) (6%)

INTERNATIONAL 3,434 2,981 15% 9%

WORLDWIDE $8,357 $7,821 7% 5%

Year Ended

December 31, Change

As Reported Constant

Currency Currency

In millions 2007 2006 Basis Basis

Interventional Cardiology $3,117 $3,612 (14%) (15%)

Peripheral Interventions/

Vascular Surgery 627 666 (6%) (9%)

Electrophysiology 147 134 10% 8%

Neurovascular 352 326 8% 4%

Cardiac Surgery 194 132 47% 47%

Cardiac Rhythm Management 2,124 1,371 55% 51%

CARDIOVASCULAR 6,561 6,241 5% 3%

Oncology 233 221 5% 3%

Endoscopy 843 754 12% 9%

Urology 403 371 9% 8%

ENDOSURGERY 1,479 1,346 10% 7%

NEUROMODULATION 317 234 36% 33%

WORLDWIDE $8,357 $7,821 7% 5%

Growth rates are based on actual, non-rounded amounts

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

Q4 2007 Net Sales as compared to Q4 2006

Change Estimated

As Reported Constant Impact of

Currency Currency Foreign

In millions Basis Basis Currency

DOMESTIC $(35) $(35)

Europe 53 6 $47

Asia Pacific 64 48 16

Inter-Continental 5 (7) 12

INTERNATIONAL 122 47 75

WORLDWIDE $87 $12 $75

Q4 2007 Net Sales as compared to Q4 2006

Change Estimated

As Reported Constant Impact of

Currency Currency Foreign

In millions Basis Basis Currency

Interventional Cardiology $(46) $(74) $28

Peripheral Interventions/

Vascular Surgery (2) (8) 6

Electrophysiology 3 3 -

Neurovascular 9 3 6

Cardiac Surgery 1 2 (1)

Cardiac Rhythm Management 55 36 19

CARDIOVASCULAR 20 (38) 58

Oncology 5 2 3

Endoscopy 25 15 10

Urology 10 8 2

ENDOSURGERY 40 25 15

NEUROMODULATION 27 25 2

WORLDWIDE $87 $12 $75

An explanation of the ways in which Boston Scientific management uses

these non-GAAP measures to evaluate its business, the substance behind

Boston Scientific management's decision to use these non-GAAP measures,

Fourth Quarter 2007

Net sales for the fourth quarter of 2007 were $2.152 billion, as compared to $2.065 billion for the fourth quarter of 2006. Worldwide sales of the Company's drug-eluting coronary stent systems were $435 million, as compared to $506 million. U.S. sales of drug-eluting coronary stent systems were $224 million, as compared to $329 million. International sales of drug-eluting coronary stent systems were $211 million, as compared to $177 million. Worldwide sales of coronary stent systems were $496 million, as compared to $550 million. U.S. sales of coronary stent systems were $250 million, as compared to $347 million. International sales of coronary stent systems were $246 million, as compared to $203 million.

Worldwide sales of the Company's CRM business for the fourth quarter of 2007 were $544 million, which included $396 million of implantable cardioverter defibrillator (ICD) sales, as compared to worldwide CRM sales of $489 million for the fourth quarter of 2006, which included $356 million of ICD sales. U.S. CRM sales were $347 million, which included $266 million of ICD sales, as compared to $320 million, which included $250 million of ICD sales. International CRM sales were $197 million, which included $130 million of ICD sales, as compared to $169 million, which included $106 million of ICD sales.

Reported net loss for the fourth quarter of 2007 was $458 million, or $0.31 per share. Reported results included acquisition, divestiture, litigation and restructuring-related charges and amortization expense (pre-tax) of $939 million, or $0.55 per share, which consisted of:

p>

the material limitations associated with the use of these non-GAAP

measures, the manner in which Boston Scientific management compensates for

those limitations, and the substantive reasons why Boston Scientific

management believes that these non-GAAP measures provide useful

information to investors is included in the exhibit labeled "Use of Non-

GAAP Financial Measures.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

2007 Net Sales as compared to 2006

Change Estimated

As Reported Constant Impact of

Currency Currency Foreign

In millions Basis Basis Currency

DOMESTIC $83 $83

Europe 231 87 $144

Asia Pacific 228 214 14

Inter-Continental (6) (28) 22

INTERNATIONAL 453 273 180

WORLDWIDE $536 $356 $180

2007 Net Sales as compared to 2006

Change Estimated

As Reported Constant Impact of

Currency Currency Foreign

In millions Basis Basis Currency

Interventional Cardiology $(495) $(555) $60

Peripheral Interventions/

Vascular Surgery (39) (57) 18

Electrophysiology 13 11 2

Neurovascular 26 15 11

Cardiac Surgery 62 62 -

Cardiac Rhythm Management 753 702 51

CARDIOVASCULAR 320 178 142

Oncology 12 7 5

Endoscopy 89 65 24

Urology 32 28 4

ENDOSURGERY 133 100 33

NEUROMODULATION 83 78 5

WORLDWIDE $536 $356 $180

An explanation of the ways in which Boston Scientific management uses

these non-GAAP measures to evaluate its business, the substance behind

Boston Scientific management's decision to use these non-GAAP measures,

the material limitations associated with the use of these non-GAAP

measures, the manner in which Boston Scientific management compensates for

those limitations, and the substantive reasons why Boston Scientific

management believes that these non-GAAP measures provide useful

information to investors is included in the exhibit labeled "Use of Non-

GAAP Financial Measures.

BOSTON SCIENTIFIC CORPORATION

ESTIMATED NON-GAAP NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

Q1 2008 Estimate Q1 2008 Estimate

(Low) (High)

GAAP results $0.13 $0.18

Estimated acquisition and

divestiture-related net gains (0.07) (0.07)

Estimated restructuring charges 0.02 0.02

Estimated amortization expense 0.07 0.07

Adjusted results $0.15 $0.20

An explanation of the ways in which Boston Scientific management uses

these non-GAAP measures to evaluate its business, the substance behind

Boston Scientific management's decision to use these non-GAAP measures,

the material limitations associated with the use of these non-GAAP

measures, the manner in which Boston Scientific management compensates for

those limitations, and the substantive reasons why Boston Scientific

management believes that these non-GAAP measures provide useful

information to investors is included in the exhibit labeled "Use of Non-

GAAP Financial Measures.

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's consolidated condensed financial

statements presented on a GAAP basis; the Company discloses certain non-

GAAP measures that exclude certain amounts, including non-GAAP net income,

non-GAAP net income per diluted share, and regional and divisional revenue

growth rates that exclude the impact of foreign exchange. These non-GAAP

measures are not in accordance with, or an alternative for, generally

accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income

and the GAAP measure most comparable to non-GAAP net income per diluted

share is GAAP net income per diluted share. Reconciliations of each of

these non-GAAP financial measures to the corresponding GAAP measure are

included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the

impact of foreign exchange, the Company converts actual current-period net

sales from local currency to U.S. dollars using constant foreign exchange

rates. The GAAP measure most comparable to this non-GAAP measure is growth

rate percentages based on GAAP revenue. A reconciliation of this non-GAAP

financial measure to the corresponding GAAP measure is included in the

accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston

Scientific

Management uses these supplemental non-GAAP measures to evaluate

performance period over period, to analyze the underlying trends in the

Company's business, to assess its performance relative to its competitors,

and to establish operational goals and forecasts that are used in

allocating resources. In addition, management uses these non-GAAP measures

to further its understanding of the performance of the Company's operating

segments. The adjustments excluded from the Company's non-GAAP measures

are consistent with those excluded from its reportable segments' measure

of profit or loss. These adjustments are excluded from the segment

measures that are reported to the Company's chief operating decision maker

and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management

excluded as part of its non-GAAP measures for the three and twelve month

periods ending December 31, 2007 and December 31, 2006 and for the

forecasted three month period ending March 31, 2008, as well as reasons

for excluding each of these individual items:

-- Acquisition and divestiture-related charges -- For the three and twelve

months ending December 31, 2007 and December 31, 2006, these

adjustments primarily consisted of: purchased research and development;

a loss on assets held for sale related to the Company's divestiture of

certain businesses; integration costs associated with the Company's

acquisition of Guidant; the fair value adjustment related to the

sharing of proceeds feature of the Abbott stock purchase; the step-up

value of acquired Guidant inventory sold during the period; the AAA

program cancellation net credit, which consisted of a credit to

purchased research and development and facility and severance costs

associated with the program termination; a CRM technology offering

charge to make available the Latitude(R) Patient Management System;

costs that resulted from certain business optimization initiatives

following the Company's acquisition of Guidant; and a charitable

contribution. Purchased research and development is a highly variable

charge based on valuation assumptions. Management removes the impact of

purchased research and development from the Company's operating results

to assist in assessing the Company's operating performance and cash

generated from operations. The loss on assets held for sale represents

charges associated with the sale of certain components of the Company's

Neuromodulation business and its Cardiac Surgery and Vascular Surgery

businesses, and is not indicative of future operating performance and

is not used by management to assess operating performance. The

integration costs associated with the Company's acquisition of Guidant

do not reflect expected on-going future operating expenses. The fair

value adjustment related to the sharing of proceeds feature of the

Abbott stock purchase is a non-cash adjustment and is not indicative of

the Company's on-going operations. The step-up value of acquired

inventory is a cost directly attributable to the Guidant acquisition

and is not indicative of the Company's on-going operations, or on-going

cost of products sold. The facility and severance costs related to the

AAA program cancellation do not reflect expected future operating

expenses. The CRM technology offering charge represents a one-time cost

associated with making this technology available to existing patients

and the cost is not indicative of future expenses associated with the

technology. The business optimization costs do not reflect expected

future operating expenses and Boston Scientific management excludes

them in assessing current operating performance. The charitable

contribution does not reflect expected future operating expenses.

Accordingly, management excluded these charges for purposes of

calculating these non-GAAP measures to facilitate an evaluation of the

Company's current operating performance and a comparison to the

Company's past operating performance.

-- Restructuring charges -- These expenses primarily represent employee-

related termination benefits, asset write-downs and other costs

associated with the Company's restructuring initiatives. These expenses

are not indicative of the Company's on-going operating performance and

are excluded by management in assessing the Company's operating

performance, and are also excluded from the Company's operating

segments' measures of profit and loss used for making operating

decisions and assessing performance. Accordingly, management excluded

these charges for purposes of calculating these non-GAAP measures to

facilitate an evaluation of the Company's current operating performance

and a comparison to the Company's past operating performance.

-- Litigation-related charges -- These charges are attributable to

estimated potential losses associated with patent litigation involving

the Company's interventional cardiology business. These amounts

represent significant one-time charges during the fourth quarter of

2007 and do not reflect expected on-going operating expenses.

Accordingly, management excluded these charges for purposes of

calculating these non-GAAP measures to facilitate an evaluation of the

Company's current operating performance and for comparison to the

Company's past operating performance.

-- Amortization expense -- Amortization expense is a non-cash charge and

does not impact the Company's liquidity or compliance with the

covenants included in its debt agreements. Following the Company's

acquisition of Guidant, and the related increase in the Company's debt,

management has heightened its focus on cash generation and debt pay

down. Management removes the impact of amortization from the Company's

operating performance to assist in assessing the Company's cash

generated from operations. Management believes this is a critical

metric for the Company in measuring the Company's ability to generate

cash and pay down debt. Therefore, amortization expense is excluded

from management's assessment of operating performance and is also

excluded from the measures management uses to set employee

compensation. Accordingly, management believes this may be useful

information to users of its financial statements and therefore has

excluded these charges for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance, particularly in terms of liquidity.

-- Foreign exchange on net sales -- The impact of foreign exchange is

highly variable and difficult to predict. Accordingly, management

excludes the impact of foreign exchange for purposes of reviewing

regional and divisional revenue growth rates to facilitate an

evaluation of the Company's current operating performance and

comparison to the Company's past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial

Measures

Non-GAAP net income, non-GAAP net income per diluted share, and regional

and divisional revenue growth rates that exclude the impact of foreign

exchange may have limitations as analytical tools, and these non-GAAP

measures should not be considered in isolation or as a replacement for

GAAP financial measures. Some of the limitations associated with the use

of these non-GAAP financial measures are:

-- Items such as purchased research and development, the step-up value of

acquired Guidant inventory sold during the period, the CRM technology

offering charge, the loss on assets held for sale, and the fair value

adjustment related to the sharing of proceeds feature of the Abbott

stock purchase reflect economic costs to the Company and are not

reflected in non-GAAP net income and non-GAAP net income per diluted

share.

-- Items such as Guidant integration costs, facility and severance costs,

employee-related costs associated with certain business optimization

initiatives, the charitable contribution, and restructuring and

litigation-related expenses that are excluded from non-GAAP net income

and non-GAAP net income per diluted share can have a material impact on

cash flows and GAAP net income and net income per diluted share.

-- Items such as amortization of purchased intangible assets, though not

directly affecting Boston Scientific's cash flow position, represent a

reduction in value of intangible assets over time. The expense

associated with this reduction in value is not included in Boston

Scientific's non-GAAP net income or non-GAAP net income per diluted

share and therefore these measures do not reflect the full economic

effect of the reduction in value of those intangible assets.

-- Revenue growth rates stated on a constant currency basis, by their

nature, exclude the impact of foreign exchange, which may have a

material impact on GAAP net sales.

-- Other companies may calculate non-GAAP net income, non-GAAP net income

per diluted share, or regional and divisional revenue growth rates that

exclude the impact of foreign exchange differently than Boston

Scientific does, limiting the usefulness of those measures for

comparative purposes.

Compensation for Limitations Associated with Use of Non-GAAP Financial

Measures

Boston Scientific compensates for the limitations on its non-GAAP

financial measures by relying upon its GAAP results to gain a complete

picture of the Company's performance. The non-GAAP numbers focus instead

upon the core business of the Company, which is only a subset, albeit a

critical one, of the Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial

measure to its most directly comparable GAAP measure in the accompanying

schedules, and Boston Scientific encourages investors to review these

reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income, non-GAAP net

income per share, and regional and divisional revenue growth rates that

exclude the impact of foreign exchange in addition to the related GAAP

measures provides investors greater transparency to the information used

by Boston Scientific management for its financial and operational

decision-making and allows investors to see Boston Scientific's results

"through the eyes" of management. The Company further believes that

providing this information better enables Boston Scientific's investors to

understand the Company's operating performance and to evaluate the

methodology used by management to evaluate and measure such performance.

Disclosure of these non-GAAP financial measures may also facilitate

comparisons of Boston Scientific's operating performance with the

performance of other companies that supplement their GAAP results with

non-GAAP financial measures.

-- $208 million, primarily non-cash, associated with the write down of

goodwill in connection with business divestitures;

-- $8 million of other net acquisition-related charges;

-- $365 million attributable to estimated potential losses associated with

patent litigation involving the Company's Interventional Cardiology

business;

-- $184 million of restructuring charges associated with the Company's

expense and head count reduction initiatives; and

-- $174 million of amortization expense.

Adjusted net income for the quarter, excluding these charges and amortization expense, was $355 million, or $0.24 per share.

Reported net income for the fourth quarter of 2006 was $277 million, or $0.19 per share. Reported results included charges associated with the Company's 2006 acquisition of Guidant Corporation and amortization expense (pre-tax) of $197 million, or $0.11 per share. Adjusted net income for the fourth quarter of 2006, excluding these charges and amortization expense, was $442 million, or $0.30 per share.

Full Year 2007

Net sales for the full year 2007 were $8.357 billion, as compared to $7.821 billion in 2006. Worldwide sales of the Company's drug-eluting coronary stent systems were $1.788 billion, as compared to $2.358 billion. U.S. sales of drug-eluting coronary stent systems were $1.006 billion, as compared to $1.561 billion. International sales of drug-eluting coronary stent systems were $782 million, as compared to $797 million. Worldwide sales of coronary stent systems were $2.027 billion, as compared to $2.506 billion. U.S. sales of coronary stent systems were $1.110 billion, as compared to $1.613 billion. International sales of coronary stent systems were $917 million, as compared to $893 million.

Worldwide sales of the Company's CRM business in 2007 were $2.124 billion, which included $1.542 billion of ICD sales, as compared to $1.371 billion in 2006, which included $988 million of ICD sales. On a pro forma basis for 2006 -- as though the Company had acquired Guidant on January 1, 2006 -- CRM sales were $2.026 billion, which included $1.473 billion of ICD sales. U.S. CRM sales in 2007 were $1.371 billion, which included $1.053 billion of ICD sales, as compared to U.S. CRM sales of $908 million, which included $696 million of ICD sales. Pro forma U.S. CRM sales were $1.358 billion, which included $1.053 billion of ICD sales. International CRM sales in 2007 were $753 million, which included $489 million of ICD sales, as compared to international CRM sales of $463 million, which included $292 million of ICD sales. Pro forma international CRM sales were $668 million, which included $420 million of ICD sales.

Reported net loss for 2007 was $495 million, or $0.33 per share. Reported results for 2007 included acquisition, divestiture, litigation and restructuring-related charges, and amortization expense (pre-tax) of $1.9 billion, or $1.10 per share, which consisted of:

-- $560 million, primarily non-cash, associated with the write down of

goodwill in connection with business divestitures;

-- $85 million in-process research and development write offs, related

primarily to the Company's acquisition of Remon Medical Technologies,

Inc.;

-- $37 million related to the Company's acquisition of Guidant;

-- $365 million attributable to estimated potential losses associated with

patent litigation involving the Company's Interventional Cardiology

business;

-- $184 million of restructuring charges associated with the Company's

expense and head count reduction initiatives; and

-- $641 million of amortization expense.

Adjusted net income for 2007, excluding these charges and amortization expense, was $1.2 billion, or $0.77 per share.

Reported net loss for 2006 was $3.6 billion, or $2.81 per share. Reported results for 2006 included acquisition-related charges and amortization expense (pre-tax) of $5.2 billion, or $3.90 per share. Adjusted net income for 2006, excluding these charges and amortization expense, was $1.4 billion, or $1.09 per share.

Guidance for First Quarter 2008

The Company estimates net sales for the first quarter of 2008 of between $1.96 billion and $2.08 billion. Adjusted earnings, excluding acquisition, divestiture, litigation and restructuring-related charges, and amortization expense, are estimated to range between $0.15 and $0.20 per share. The Company estimates net income on a GAAP basis of between $0.13 and $0.18 per share.

Full-year 2008 sales and earnings per share guidance will be provided during the Company's conference call with analysts tomorrow.

Boston Scientific officials will be discussing these results with analysts on a conference call at 8:30 am. (ET) Tuesday, February 5, 2008. The Company will webcast the call to all interested parties through its website: http://www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one year on the Boston Scientific website.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our restructuring plan, our programs to increase shareholder value, new product approvals, litigation, our growth strategy, market recovery and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

To supplement Boston Scientific's consolidated condensed financial statements presented on a GAAP basis, the Company discloses certain non-GAAP measures that exclude certain charges, including non-GAAP net income/loss and non-GAAP net income/loss per diluted share. These non-GAAP measures are not in accordance with, or an alternative for, generally accepted accounting principles in the United States. A reconciliation of the non-GAAP financial measures to the corresponding GAAP measures is included in the tables below. In addition, an explanation of the ways in which Boston Scientific management uses these non-GAAP measures to evaluate its business, the substance behind Boston Scientific management's decision to use these non-GAAP measures, the material limitations associated with the use of these non-GAAP measures, the manner in which Boston Scientific management compensates for those limitations, and the substantive reasons why Boston Scientific management believes that these non-GAAP measures provide useful information to investors is included under "Use of Non-GAAP Financial Measures" after the tables below. This additional non-GAAP financial information is not meant to be considered in isolation or as a substitute for financial information prepared in accordance with GAAP.

CONTACT:

Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Dan Brennan

508-650-8538 (office)

Investor Relations

Boston Scientific Corporation

BOSTON SCIENTIFIC CORPORATION

CONDENSED GAAP RESULTS OF OPERATIONS

(Unaudited)

Three Months Ended

December 31,

In millions, except per share data 2007 2006

Net sales $2,152 $2,065

Cost of products sold 635 526

Gross profit 1,517 1,539

Operating expenses

Selling, general and administrative expenses 704 758

Research and development expenses 256 267

Royalty expense 51 54

Amortization expense 174 174

Purchased research and development 13 2

Restructuring charges 176

Litigation-related charges 365

Loss on assets held for sale 208

1,947 1,255

Operating (loss) income (430) 284

Other income (expense):

Interest expense (137) (144)

Other, net (29) 29

(Loss) income before income taxes (596) 169

Income tax benefit (138) (108)

Net (loss) income $(458) $277

Net (loss) income per common share -

assuming dilution $(0.31) $0.19

Weighted average shares outstanding -

assuming dilution 1,490.8 1,493.6

BOSTON SCIENTIFIC CORPORATION NON-GAAP NET (LOSS) INCOME AND NET (LOSS) INCOME PER SHARE RECONCILIATIONS

(Unaudited)

An explanation of the ways in which Boston Scientific management uses

these non-GAAP measures to evaluate its business, the substance behind

Boston Scientific management's decision to use these non-GAAP measures,

the material limitations associated with the use of these non-GAAP

measures, the manner in which Boston Scientific management compensates for

those limitations, and the substantive reasons why Boston Scientific

management believes that these non-GAAP measures provide useful

information to investors is included in the exhibit labeled "Use of Non-

GAAP Financial Measures.

Three Months Ended Three Months Ended

December 31, 2007 December 31, 2006

Net Impact per Impact per

income diluted Net diluted

In millions, except per share data (loss) share income share

GAAP results $(458) $(0.31) $277 $0.19

Non-GAAP adjustments:

Acquisition and divestiture-

related charges 211 0.14 23 0.02

Restructuring charges 131 0.09

Litigation-related charges 294 0.20

Amortization expense 177 0.12 142 0.09

Adjusted results $355 $0.24 (1) $442 $0.30

(1) Calculated by assuming stock-based dilution of 9.0 million shares

Three Months Ended

December 31,

2007 2006'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Participate in Merrill Lynch Conference
2. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
3. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
5. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
6. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
7. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
8. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
9. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
10. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
11. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... With a presidential election in November and the ... will bring together over 500 top healthcare leaders for a night and day of ... organized by MBA students of the University of Pennsylvania’s Wharton School, will be held ...
(Date:2/9/2016)... of Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Business Development, Europe. Based in Paris, he will focus on acquiring new accounts ... are being met. , “Fred brings to our European clients more ...
(Date:2/9/2016)... 2016 This market research report on the ... prospects of the market in terms of revenue (USD ... in the manufacture of microbiology culture media and related ... market snapshot providing the overall information of various market ... section also provides the overall information and data analysis ...
(Date:2/8/2016)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... technology companies in the TSX Venture 50 TM . ... the TSX Venture Exchange, in each of five major industry ... & life sciences, diversified industries and technology – based on ... investment, market cap growth, trading volume and analyst coverage. All ...
Breaking Biology Technology:
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... 2016 Rising sales of consumer ... touchfree intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ... size through 2020   --> ... technological advancements to drive global touchfree intuitive gesture control ...
Breaking Biology News(10 mins):